Insights

Innovative Oncology Platforms Champions Oncology's proprietary TumorGraft® PDX models and AI-driven therapeutic discovery platform position it as a leader in personalized cancer research, creating opportunities to offer advanced diagnostic tools, biomarker development, and tailored drug testing solutions.

Strategic Industry Collaborations Active partnerships with renowned institutions like Weill Cornell Medicine and companies such as Turbine and Biovolume indicate a collaborative approach, opening avenues for joint research initiatives, licensing opportunities, and integrated service offerings.

Recent Expansion into Radiopharmaceuticals The recent launch of a radiopharmaceutical services platform and isotope licensing expansion suggest growth in niche treatment modalities, providing prospects for specialized imaging, targeted therapy solutions, and companion diagnostic development.

Growth and Market Position With revenue estimates between 50 million and 100 million USD and a substantial research and development focus, Champions Oncology offers potential for scalable solutions, including high-throughput drug screening, genomic analysis services, and related biotech support products.

Leadership and Innovation The appointment of a new President and ongoing technology integrations demonstrate a strategic focus on growth and innovation, presenting opportunities to collaborate on cutting-edge projects in oncology therapeutics, data analytics, and personalized medicine solutions.

Similar companies to Champions Oncology, Inc.

Champions Oncology, Inc. Tech Stack

Champions Oncology, Inc. uses 8 technology products and services including Cloudflare CDN, jsDelivr, Unpkg, and more. Explore Champions Oncology, Inc.'s tech stack below.

  • Cloudflare CDN
    Content Delivery Network
  • jsDelivr
    Content Delivery Network
  • Unpkg
    Content Delivery Network
  • Microsoft Excel
    Editors
  • Microsoft Dynamics
    Enterprise Resource Planning
  • Twemoji
    Font Scripts
  • petite-vue
    Miscellaneous
  • Piwik
    System Analytics & Monitoring

Media & News

Champions Oncology, Inc.'s Email Address Formats

Champions Oncology, Inc. uses at least 1 format(s):
Champions Oncology, Inc. Email FormatsExamplePercentage
FLast@championsoncology.comJDoe@championsoncology.com
94%
F.Last@championsoncology.comJ.Doe@championsoncology.com
5%
First.Last@championsoncology.comJohn.Doe@championsoncology.com
1%

Frequently Asked Questions

What is Champions Oncology, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Champions Oncology, Inc. is a publicly traded company; the company's stock symbol is CSBR.

What is Champions Oncology, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Champions Oncology, Inc.'s official website is championsoncology.com and has social profiles on LinkedInCrunchbase.

How much revenue does Champions Oncology, Inc. generate?

Minus sign iconPlus sign icon
As of January 2026, Champions Oncology, Inc.'s annual revenue is estimated to be $11M.

What is Champions Oncology, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Champions Oncology, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Champions Oncology, Inc. have currently?

Minus sign iconPlus sign icon
As of January 2026, Champions Oncology, Inc. has approximately 178 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Cfo: D. M.Chief Operating Officer: M. M.Chief Commercial Officer: M. R.. Explore Champions Oncology, Inc.'s employee directory with LeadIQ.

What industry does Champions Oncology, Inc. belong to?

Minus sign iconPlus sign icon
Champions Oncology, Inc. operates in the Biotechnology Research industry.

What technology does Champions Oncology, Inc. use?

Minus sign iconPlus sign icon
Champions Oncology, Inc.'s tech stack includes Cloudflare CDNjsDelivrUnpkgMicrosoft ExcelMicrosoft DynamicsTwemojipetite-vuePiwik.

What is Champions Oncology, Inc.'s email format?

Minus sign iconPlus sign icon
Champions Oncology, Inc.'s email format typically follows the pattern of FLast@championsoncology.com. Find more Champions Oncology, Inc. email formats with LeadIQ.

When was Champions Oncology, Inc. founded?

Minus sign iconPlus sign icon
Champions Oncology, Inc. was founded in 2007.

Champions Oncology, Inc.

Biotechnology ResearchNew Jersey, United States51-200 Employees

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios.

From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.

At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations.

Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business.

Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CSBR
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2007
Employees
51-200

Section iconFunding & Financials

  • $50M$100M

    Champions Oncology, Inc.'s revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Champions Oncology, Inc.'s revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.